theophylline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
N-methylated xanthine derivatives 2620 58-55-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aminophyllin
  • aminophylline
  • theophylline
  • 1,3-Dimethylxanthine
  • armophylline
  • cetraphylline
  • chronophyllin
  • duraphyllin
  • elixophyllin
  • elixophylline
  • etheophyl
  • lanophyllin
  • pseudotheophylline
  • theophyllin
  • throphylline
  • xanthium
  • theophylline anhydrous
  • aminophylline dihydrate
  • theophylline sodium glycinate
  • theophylline monohydrate
A plant genus of the family ASTERACEAE. The name "prickly burweed" is sometimes used but causes confusion with AMSINCKIA.
  • Molecular weight: 180.17
  • Formula: C7H8N4O2
  • CLOGP: -0.03
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 69.30
  • ALOGS: -0.80
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P
0.40 g R
0.60 g O
0.60 g P
0.60 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 8.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 18 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 48.12 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.51 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.86 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.61 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 19, 1940 FDA GD SEARLE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 531.57 12.42 387 22428 88950 50493359
Wheezing 417.69 12.42 290 22525 61757 50520552
Chronic obstructive pulmonary disease 165.54 12.42 159 22656 53276 50529033
Productive cough 163.62 12.42 157 22658 52537 50529772
Dyspnoea 161.27 12.42 576 22239 547032 50035277
Sputum discoloured 127.71 12.42 78 22737 13317 50568992
Breath sounds abnormal 119.57 12.42 62 22753 7730 50574579
Forced expiratory volume decreased 113.45 12.42 50 22765 4344 50577965
Rales 113.17 12.42 65 22750 9913 50572396
Sinus tachycardia 112.07 12.42 86 22729 21268 50561041
Bronchial neoplasm 96.52 12.42 25 22790 408 50581901
Chest discomfort 94.18 12.42 158 22657 92564 50489745
Bronchial haemorrhage 91.98 12.42 25 22790 495 50581814
Nasal turbinate hypertrophy 90.15 12.42 26 22789 644 50581665
Nasal congestion 80.48 12.42 107 22708 51013 50531296
Endometrial ablation 79.47 12.42 25 22790 838 50581471
Sleep disorder due to a general medical condition 78.24 12.42 46 22769 7325 50574984
Hypercapnia 77.32 12.42 39 22776 4588 50577721
Cough 76.73 12.42 261 22554 241003 50341306
Bronchial disorder 76.50 12.42 26 22789 1116 50581193
Obstructive airways disorder 75.54 12.42 60 22755 15592 50566717
Rhonchi 71.92 12.42 30 22785 2277 50580032
Prolonged expiration 66.87 12.42 21 22794 700 50581609
Heart sounds 65.38 12.42 20 22795 610 50581699
Status asthmaticus 63.89 12.42 21 22794 812 50581497
Alopecia 61.85 12.42 17 22798 245030 50337279
Bronchitis chronic 57.05 12.42 30 22785 3847 50578462
Pulmonary pain 55.46 12.42 25 22790 2290 50580019
Neurosensory hypoacusis 54.97 12.42 14 22801 213 50582096
Systemic lupus erythematosus 51.33 12.42 3 22812 140619 50441690
Pneumonia 49.24 12.42 315 22500 378086 50204223
Joint swelling 48.57 12.42 25 22790 245261 50337048
Rheumatoid arthritis 47.58 12.42 16 22799 202534 50379775
Rhinitis 47.01 12.42 35 22780 8266 50574043
Occupational asthma 46.90 12.42 11 22804 116 50582193
Lower respiratory tract infection 46.43 12.42 120 22695 95081 50487228
Toxicity to various agents 46.25 12.42 204 22611 212295 50370014
Granuloma 45.56 12.42 28 22787 4830 50577479
Respiratory rate increased 45.25 12.42 39 22776 11346 50570963
Airway peak pressure increased 42.16 12.42 12 22803 283 50582026
Treatment failure 42.10 12.42 6 22809 137631 50444678
Bronchospasm 41.84 12.42 42 22773 14812 50567497
Depressed mood 41.39 12.42 63 22752 33960 50548349
Dyspnoea exertional 41.31 12.42 79 22736 51154 50531155
Multiple drug therapy 40.40 12.42 19 22796 1918 50580391
Respiratory acidosis 40.04 12.42 28 22787 6000 50576309
Drug interaction 39.96 12.42 187 22628 199434 50382875
Lung hyperinflation 39.83 12.42 16 22799 1102 50581207
PCO2 increased 39.49 12.42 16 22799 1127 50581182
Middle insomnia 39.46 12.42 34 22781 9887 50572422
Depressive symptom 39.39 12.42 22 22793 3178 50579131
Pain 39.38 12.42 132 22683 578771 50003538
Respiration abnormal 39.37 12.42 26 22789 5076 50577233
Increased viscosity of bronchial secretion 39.04 12.42 11 22804 250 50582059
Affective disorder 39.00 12.42 26 22789 5155 50577154
Fatigue 38.79 12.42 176 22639 707425 49874884
Exercise tolerance decreased 38.00 12.42 25 22790 4849 50577460
Bronchial obstruction 37.62 12.42 16 22799 1274 50581035
Acute respiratory failure 37.45 12.42 55 22760 28727 50553582
Lipohypertrophy 37.34 12.42 13 22802 600 50581709
Eosinophil count increased 36.62 12.42 31 22784 8799 50573510
Oesophageal dilatation 36.39 12.42 11 22804 322 50581987
Decreased bronchial secretion 36.20 12.42 8 22807 63 50582246
Infusion related reaction 35.50 12.42 16 22799 169541 50412768
Congestive cardiomyopathy 35.19 12.42 25 22790 5493 50576816
Off label use 35.17 12.42 104 22711 474322 50107987
Respiratory tract inflammation 35.02 12.42 12 22803 528 50581781
Rash 34.56 12.42 93 22722 437378 50144931
Eosinophilic granulomatosis with polyangiitis 34.20 12.42 17 22798 1938 50580371
Respiratory disorder 34.12 12.42 55 22760 31132 50551177
Swelling 33.48 12.42 25 22790 200847 50381462
PO2 decreased 33.36 12.42 15 22800 1366 50580943
Blood pressure inadequately controlled 33.02 12.42 22 22793 4358 50577951
Adrenal suppression 32.88 12.42 13 22802 859 50581450
Contraindicated product administered 32.87 12.42 13 22802 148945 50433364
Synovitis 32.35 12.42 8 22807 123857 50458452
Drug ineffective 32.31 12.42 227 22588 819106 49763203
Arteriosclerosis coronary artery 32.06 12.42 27 22788 7609 50574700
Hepatic enzyme increased 31.98 12.42 11 22804 137369 50444940
Respiratory failure 31.88 12.42 102 22713 91079 50491230
Emphysema 31.85 12.42 29 22786 9064 50573245
Vital capacity decreased 31.72 12.42 13 22802 943 50581366
Tachycardia 31.67 12.42 108 22707 99655 50482654
Female sterilisation 31.65 12.42 11 22804 505 50581804
Stress cardiomyopathy 31.30 12.42 27 22788 7860 50574449
Asthmatic crisis 31.00 12.42 15 22800 1613 50580696
Blood bicarbonate decreased 28.90 12.42 17 22798 2708 50579601
Ligament pain 28.38 12.42 8 22807 182 50582127
Blood pH decreased 27.85 12.42 16 22799 2439 50579870
Breast neoplasm 27.76 12.42 13 22802 1300 50581009
Viral infection 27.65 12.42 49 22766 29937 50552372
Arthropathy 27.15 12.42 19 22796 157887 50424422
Product use issue 27.03 12.42 17 22798 149458 50432851
Drug level increased 26.79 12.42 38 22777 19230 50563079
Dyspnoea at rest 26.73 12.42 18 22797 3629 50578680
Drug intolerance 26.53 12.42 36 22779 219068 50363241
Left ventricular failure 26.49 12.42 20 22795 4821 50577488
Appetite disorder 26.46 12.42 22 22793 6092 50576217
Sinus pain 26.36 12.42 15 22800 2246 50580063
Oligoarthritis 26.34 12.42 8 22807 238 50582071
Eosinophilia 26.25 12.42 37 22778 18615 50563694
Rhinorrhoea 26.14 12.42 66 22749 51517 50530792
Drug level above therapeutic 25.55 12.42 18 22797 3902 50578407
Therapeutic product effect decreased 25.26 12.42 15 22800 136035 50446274
Diabetes mellitus 25.12 12.42 63 22752 48970 50533339
Heart rate increased 24.84 12.42 84 22731 77166 50505143
Oxygen saturation decreased 24.75 12.42 81 22734 73167 50509142
Diabetes mellitus inadequate control 24.59 12.42 30 22785 13115 50569194
Respiratory tract congestion 24.32 12.42 31 22784 14168 50568141
Full blood count abnormal 23.90 12.42 40 22775 23348 50558961
Infective exacerbation of chronic obstructive airways disease 23.51 12.42 11 22804 1097 50581212
Kyphosis 23.51 12.42 14 22801 2281 50580028
Oesophagogastroduodenoscopy 23.27 12.42 6 22809 96 50582213
Hypoventilation 23.25 12.42 17 22798 3904 50578405
Painful respiration 23.06 12.42 14 22801 2361 50579948
Abdominal discomfort 22.48 12.42 44 22771 231597 50350712
Febrile neutropenia 22.42 12.42 8 22807 97659 50484650
Pertussis 22.28 12.42 9 22806 629 50581680
Urogenital haemorrhage 22.18 12.42 7 22808 237 50582072
Spleen congestion 22.11 12.42 6 22809 118 50582191
Rhabdomyolysis 21.97 12.42 52 22763 38975 50543334
Blood lactic acid increased 21.92 12.42 19 22796 5566 50576743
Pleural rub 21.84 12.42 5 22810 47 50582262
Macrocytosis 21.83 12.42 13 22802 2117 50580192
Glossitis 21.63 12.42 14 22801 2641 50579668
Neutropenia 21.48 12.42 21 22794 147944 50434365
Completed suicide 21.22 12.42 17 22798 131872 50450437
Eye paraesthesia 21.21 12.42 5 22810 54 50582255
Cyanosis 21.19 12.42 30 22785 15154 50567155
Presbyacusis 21.06 12.42 14 22801 2762 50579547
Blood immunoglobulin E increased 20.61 12.42 13 22802 2346 50579963
Tremor 20.35 12.42 104 22711 114799 50467510
Diarrhoea 20.30 12.42 169 22646 588307 49994002
Influenza 20.22 12.42 87 22728 89451 50492858
Medication error 20.21 12.42 48 22767 36056 50546253
Lung opacity 20.12 12.42 12 22803 1961 50580348
Antasthmatic drug level above therapeutic 20.12 12.42 3 22812 0 50582309
Discomfort 20.04 12.42 12 22803 108368 50473941
Paranasal sinus hypersecretion 19.49 12.42 14 22801 3128 50579181
Myopathy 18.98 12.42 22 22793 9117 50573192
Ankle fracture 18.96 12.42 29 22786 15693 50566616
Musculoskeletal stiffness 18.92 12.42 18 22797 128463 50453846
Ventricular tachycardia 18.82 12.42 29 22786 15792 50566517
Hypokalaemia 17.99 12.42 83 22732 87909 50494400
Haemoptysis 17.69 12.42 37 22778 25536 50556773
Allergic cough 17.68 12.42 7 22808 464 50581845
Stomatitis 17.67 12.42 12 22803 101332 50480977
Bronchitis 17.55 12.42 93 22722 104066 50478243
Respiratory tract infection 17.31 12.42 42 22773 31975 50550334
Impaired healing 17.28 12.42 5 22810 69781 50512528
Increased bronchial secretion 17.24 12.42 10 22805 1552 50580757
Depressed level of consciousness 17.14 12.42 57 22758 51896 50530413
Stress urinary incontinence 17.10 12.42 11 22804 2054 50580255
Nasal oedema 16.88 12.42 8 22807 822 50581487
Pulmonary congestion 16.82 12.42 27 22788 15220 50567089
Anaphylactic reaction 16.69 12.42 58 22757 53997 50528312
Crepitations 16.45 12.42 17 22798 6202 50576107
Seizure 16.41 12.42 100 22715 117774 50464535
Staphylococcus test positive 16.31 12.42 13 22802 3393 50578916
Glaucoma 16.25 12.42 27 22788 15659 50566650
Hypercholesterolaemia 16.15 12.42 23 22792 11680 50570629
Food allergy 15.92 12.42 19 22796 8118 50574191
Flail chest 15.88 12.42 4 22811 58 50582251
Chest pain 15.88 12.42 135 22680 176747 50405562
Oropharyngeal candidiasis 15.71 12.42 8 22807 960 50581349
Cushingoid 15.51 12.42 17 22798 6628 50575681
Injection site hypoaesthesia 15.48 12.42 6 22809 376 50581933
Lung perforation 15.40 12.42 4 22811 66 50582243
Peripheral swelling 15.30 12.42 45 22770 205891 50376418
Status epilepticus 15.15 12.42 24 22791 13382 50568927
Aortic valve calcification 15.11 12.42 6 22809 401 50581908
Generalised tonic-clonic seizure 14.75 12.42 35 22780 26275 50556034
Mental disability 14.49 12.42 4 22811 84 50582225
Atopy 14.48 12.42 5 22810 225 50582084
Escherichia infection 14.36 12.42 21 22794 10920 50571389
Contraindicated product prescribed 14.15 12.42 7 22808 790 50581519
Sputum abnormal 14.13 12.42 6 22809 476 50581833
Dysphonia 14.03 12.42 44 22771 38848 50543461
Scratch 13.91 12.42 14 22801 4948 50577361
Parakeratosis 13.75 12.42 5 22810 262 50582047
Injection site pain 13.67 12.42 18 22797 111006 50471303
White blood cell count increased 13.63 12.42 46 22769 42194 50540115
Intentional product use issue 13.55 12.42 9 22806 76909 50505400
Seasonal allergy 13.55 12.42 24 22791 14652 50567657
Tendon pain 13.48 12.42 11 22804 2967 50579342
Disease progression 13.46 12.42 14 22801 95852 50486457
Upper respiratory tract infection 13.34 12.42 62 22753 65836 50516473
White blood cell count decreased 13.30 12.42 20 22795 116702 50465607
Galactorrhoea 13.29 12.42 12 22803 3711 50578598
Respiratory symptom 13.27 12.42 10 22805 2404 50579905
Supraventricular tachycardia 13.22 12.42 22 22793 12779 50569530
Vasodilation procedure 13.12 12.42 3 22812 28 50582281
Blood prolactin increased 13.10 12.42 11 22804 3088 50579221
Anaemia 13.03 12.42 64 22751 252392 50329917
Thoracic operation 12.98 12.42 4 22811 125 50582184
Hyperventilation 12.91 12.42 14 22801 5395 50576914
Amnestic disorder 12.89 12.42 5 22810 314 50581995
Weaning failure 12.84 12.42 5 22810 317 50581992
Atrial fibrillation 12.72 12.42 84 22731 101661 50480648
Hallucination, visual 12.66 12.42 25 22790 16557 50565752
Haemoglobin decreased 12.47 12.42 24 22791 127192 50455117

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 544.40 13.81 289 14832 33560 29525846
Wheezing 248.56 13.81 174 14947 33066 29526340
Chronic obstructive pulmonary disease 209.79 13.81 171 14950 40784 29518622
Obstructive airways disorder 162.51 13.81 89 15032 10927 29548479
Forced expiratory volume decreased 143.31 13.81 54 15067 2759 29556647
Dyspnoea 126.24 13.81 409 14712 326323 29233083
Right atrial hypertrophy 120.28 13.81 32 15089 510 29558896
Bronchial wall thickening 107.56 13.81 34 15087 1018 29558388
Productive cough 105.15 13.81 103 15018 31156 29528250
Bronchial secretion retention 104.49 13.81 34 15087 1119 29558287
Full blood count abnormal 103.78 13.81 75 15046 14938 29544468
Right ventricular hypertrophy 96.22 13.81 32 15089 1129 29558277
Therapeutic product effect incomplete 88.95 13.81 105 15016 39200 29520206
Obstruction 87.44 13.81 34 15087 1892 29557514
Aortic valve stenosis 82.94 13.81 34 15087 2174 29557232
Pulmonary function test abnormal 81.42 13.81 33 15088 2049 29557357
Vital capacity decreased 78.68 13.81 21 15100 339 29559067
Sleep disorder due to a general medical condition 77.54 13.81 36 15085 3110 29556296
Loss of personal independence in daily activities 71.30 13.81 76 15045 25364 29534042
Chest X-ray abnormal 71.13 13.81 36 15085 3758 29555648
Diastolic dysfunction 66.71 13.81 38 15083 5026 29554380
Gastrooesophageal reflux disease 66.09 13.81 81 15040 31415 29527991
Cough 65.08 13.81 176 14945 126551 29432855
Intervertebral disc degeneration 60.09 13.81 36 15085 5228 29554178
Sputum discoloured 57.62 13.81 38 15083 6525 29552881
Bronchiectasis 55.09 13.81 37 15084 6548 29552858
Foetal malformation 54.89 13.81 13 15108 125 29559281
Rhinitis perennial 53.78 13.81 14 15107 204 29559202
Respiratory failure 51.94 13.81 137 14984 96994 29462412
Mental disability 51.70 13.81 10 15111 31 29559375
Trisomy 18 50.36 13.81 13 15108 183 29559223
Forced vital capacity decreased 49.95 13.81 17 15104 644 29558762
Pulmonary function test decreased 48.90 13.81 29 15092 4134 29555272
Osteoporosis 48.89 13.81 42 15079 10727 29548679
Eosinophil count increased 40.25 13.81 32 15089 7337 29552069
Benign prostatic hyperplasia 40.11 13.81 39 15082 11671 29547735
Atrial fibrillation 38.38 13.81 130 14991 105516 29453890
Chest discomfort 37.96 13.81 77 15044 45906 29513500
Gout 36.28 13.81 44 15077 16867 29542539
Supraventricular tachycardia 35.90 13.81 34 15087 9850 29549556
Total lung capacity abnormal 34.91 13.81 9 15112 126 29559280
Eosinophilic granulomatosis with polyangiitis 34.59 13.81 16 15105 1370 29558036
Ocular discomfort 34.53 13.81 17 15104 1672 29557734
Sleep apnoea syndrome 33.30 13.81 43 15078 17556 29541850
Adjustment disorder 32.84 13.81 14 15107 987 29558419
Emphysema 29.92 13.81 29 15092 8642 29550764
Off label use 29.73 13.81 69 15052 300731 29258675
Seasonal allergy 29.69 13.81 23 15098 5079 29554327
Dyspnoea exertional 28.80 13.81 60 15061 36430 29522976
Tachycardia foetal 28.38 13.81 9 15112 272 29559134
Eosinophilic bronchitis 27.90 13.81 8 15113 170 29559236
Sputum increased 26.84 13.81 15 15106 1912 29557494
Wolff-Parkinson-White syndrome 26.79 13.81 8 15113 197 29559209
Blood immunoglobulin E increased 26.69 13.81 15 15106 1932 29557474
Hypercapnia 26.61 13.81 19 15102 3707 29555699
Foetal distress syndrome 26.40 13.81 12 15109 987 29558419
Lung hyperinflation 25.47 13.81 11 15110 801 29558605
Hypoacusis 25.36 13.81 34 15087 14389 29545017
Tachycardia 25.30 13.81 88 15033 72322 29487084
Diarrhoea 24.33 13.81 88 15033 332610 29226796
Anxiety 24.21 13.81 97 15024 85268 29474138
Pneumonia 23.83 13.81 259 14862 319913 29239493
Febrile neutropenia 23.70 13.81 14 15107 112226 29447180
Dermatitis allergic 23.44 13.81 21 15100 5667 29553739
Bronchial obstruction 22.62 13.81 12 15109 1379 29558027
Hypoxia 22.46 13.81 64 15057 47315 29512091
Conduction disorder 22.08 13.81 13 15108 1827 29557579
Neutropenia 21.94 13.81 21 15100 131690 29427716
Arrhythmia 21.86 13.81 49 15072 31264 29528142
Drug level increased 21.19 13.81 36 15085 18751 29540655
Supraventricular extrasystoles 21.01 13.81 15 15106 2926 29556480
Tachyarrhythmia 20.88 13.81 15 15106 2954 29556452
Eye pruritus 19.87 13.81 17 15104 4315 29555091
Pancytopenia 19.58 13.81 9 15112 83159 29476247
Product use in unapproved indication 19.55 13.81 10 15111 86865 29472541
Lung diffusion disorder 18.66 13.81 5 15116 82 29559324
Obesity 18.50 13.81 24 15097 9839 29549567
Perfume sensitivity 18.33 13.81 5 15116 88 29559318
Tonic convulsion 17.89 13.81 9 15112 927 29558479
Carbon dioxide increased 17.55 13.81 9 15112 965 29558441
Dermatitis atopic 17.44 13.81 12 15109 2207 29557199
Glaucoma 17.29 13.81 18 15103 5839 29553567
Ventricular extrasystoles 17.18 13.81 24 15097 10558 29548848
Pain 17.15 13.81 39 15082 171393 29388013
Lung opacity 17.14 13.81 10 15111 1382 29558024
Somnambulism 17.12 13.81 13 15108 2785 29556621
Epidural lipomatosis 17.10 13.81 8 15113 703 29558703
Unmasking of previously unidentified disease 16.97 13.81 8 15113 715 29558691
Axial spondyloarthritis 16.66 13.81 6 15115 269 29559137
Status asthmaticus 16.31 13.81 6 15115 286 29559120
Gastrointestinal necrosis 16.24 13.81 13 15108 3009 29556397
Lipid metabolism disorder 15.89 13.81 6 15115 308 29559098
Acute kidney injury 15.73 13.81 76 15045 265191 29294215
Eosinophilic pneumonia chronic 15.44 13.81 5 15116 162 29559244
Vitamin D increased 15.14 13.81 4 15117 62 29559344
Nikolsky's sign 14.91 13.81 5 15116 181 29559225
Thrombocytopenia 14.88 13.81 29 15092 134794 29424612
Loss of proprioception 14.87 13.81 6 15115 368 29559038
Neuropathy peripheral 14.79 13.81 9 15112 71018 29488388
Haemophilus infection 14.77 13.81 8 15113 959 29558447
Oropharyngeal candidiasis 14.64 13.81 7 15114 646 29558760
Hypercholesterolaemia 14.18 13.81 18 15103 7220 29552186
Sputum purulent 13.94 13.81 6 15115 433 29558973
Electrocardiogram repolarisation abnormality 13.91 13.81 7 15114 721 29558685

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 811.65 12.23 544 33083 94681 64370424
Wheezing 552.15 12.23 403 33224 80176 64384929
Chronic obstructive pulmonary disease 308.17 12.23 272 33355 70776 64394329
Productive cough 223.64 12.23 231 33396 72972 64392133
Forced expiratory volume decreased 220.16 12.23 95 33532 6772 64458333
Dyspnoea 206.33 12.23 828 32799 717846 63747259
Obstructive airways disorder 181.64 12.23 126 33501 23059 64442046
Sputum discoloured 137.42 12.23 96 33531 17760 64447345
Sleep disorder due to a general medical condition 135.38 12.23 72 33555 8162 64456943
Right atrial hypertrophy 119.47 12.23 32 33595 513 64464592
Cough 108.48 12.23 375 33252 301773 64163332
Sinus tachycardia 108.13 12.23 107 33520 32081 64433024
Breath sounds abnormal 104.71 12.23 69 33558 11600 64453505
Bronchial wall thickening 101.46 12.23 38 33589 1869 64463236
Rales 94.75 12.23 72 33555 15157 64449948
Bronchial neoplasm 92.35 12.23 25 33602 418 64464687
Right ventricular hypertrophy 91.56 12.23 32 33595 1288 64463817
Obstruction 91.38 12.23 41 33586 3207 64461898
Full blood count abnormal 90.95 12.23 94 33533 29663 64435442
Chest discomfort 90.42 12.23 192 33435 115914 64349191
Nasal turbinate hypertrophy 85.90 12.23 25 33602 550 64464555
Nasal congestion 85.75 12.23 129 33498 59529 64405576
Hypercapnia 85.28 12.23 52 33575 7642 64457463
Bronchial secretion retention 81.12 12.23 35 33592 2492 64462613
Endometrial ablation 77.73 12.23 25 33602 776 64464329
Aortic valve stenosis 72.34 12.23 39 33588 4541 64460564
Mental disability 71.96 12.23 14 33613 44 64465061
Rhonchi 70.58 12.23 35 33592 3428 64461677
Pulmonary function test abnormal 70.54 12.23 34 33593 3130 64461975
Bronchial haemorrhage 67.39 12.23 25 33602 1197 64463908
Eosinophil count increased 67.09 12.23 57 33570 14055 64451050
Status asthmaticus 65.36 12.23 23 33604 945 64464160
Pneumonia 62.86 12.23 502 33125 559074 63906031
Loss of personal independence in daily activities 62.47 12.23 125 33502 72329 64392776
Lung hyperinflation 60.67 12.23 25 33602 1587 64463518
Bronchial disorder 60.46 12.23 27 33600 2088 64463017
Respiratory failure 59.41 12.23 202 33425 160981 64304124
Heart sounds 59.25 12.23 19 33608 584 64464521
Rhinitis 58.52 12.23 47 33580 10718 64454387
Pulmonary pain 58.32 12.23 28 33599 2556 64462549
Therapeutic product effect incomplete 56.45 12.23 149 33478 103333 64361772
Bronchial obstruction 54.41 12.23 26 33601 2348 64462757
Prolonged expiration 53.46 12.23 19 33608 804 64464301
Chest X-ray abnormal 51.58 12.23 36 33591 6645 64458460
Emphysema 51.42 12.23 49 33578 14020 64451085
Off label use 51.00 12.23 165 33462 632641 63832464
Alopecia 48.84 12.23 13 33614 165677 64299428
Neurosensory hypoacusis 48.38 12.23 13 33614 211 64464894
Rhinitis perennial 47.87 12.23 13 33614 220 64464885
Febrile neutropenia 47.79 12.23 19 33608 187638 64277467
Atrial fibrillation 47.67 12.23 196 33431 170893 64294212
Tachycardia 47.03 12.23 178 33449 149401 64315704
Seasonal allergy 47.01 12.23 43 33584 11683 64453422
Neutropenia 46.81 12.23 34 33593 239590 64225515
Diastolic dysfunction 46.66 12.23 38 33589 8837 64456268
Benign prostatic hyperplasia 45.59 12.23 38 33589 9127 64455978
Lower respiratory tract infection 45.40 12.23 130 33497 94484 64370621
Dyspnoea exertional 45.23 12.23 111 33516 73619 64391486
Supraventricular tachycardia 44.36 12.23 52 33575 18855 64446250
Eosinophilic granulomatosis with polyangiitis 44.01 12.23 24 33603 2858 64462247
Respiratory rate increased 43.99 12.23 51 33576 18280 64446825
Sleep apnoea syndrome 43.55 12.23 65 33562 29767 64435338
Bronchospasm 43.35 12.23 55 33572 21627 64443478
Airway peak pressure increased 43.13 12.23 13 33614 324 64464781
Forced vital capacity decreased 42.21 12.23 19 33608 1497 64463608
Depressed mood 41.81 12.23 76 33551 40936 64424169
Vital capacity decreased 41.62 12.23 17 33610 1055 64464050
Rheumatoid arthritis 41.24 12.23 17 33610 164277 64300828
Osteoporosis 40.41 12.23 76 33551 42004 64423101
Respiration abnormal 39.59 12.23 30 33597 6285 64458820
Drug level increased 39.57 12.23 67 33560 34129 64430976
Respiratory disorder 39.48 12.23 69 33558 36042 64429063
Pulmonary function test decreased 38.98 12.23 30 33597 6431 64458674
Joint swelling 38.97 12.23 33 33594 215349 64249756
Bronchiectasis 38.47 12.23 42 33585 14098 64451007
Pain 38.14 12.23 154 33473 553357 63911748
Diarrhoea 37.71 12.23 222 33405 722482 63742623
PCO2 increased 37.43 12.23 18 33609 1649 64463456
Respiratory acidosis 37.31 12.23 35 33592 9820 64455285
Infusion related reaction 36.70 12.23 20 33607 164447 64300658
Gout 36.15 12.23 50 33577 21363 64443742
Decreased bronchial secretion 34.82 12.23 8 33619 65 64465040
Middle insomnia 34.60 12.23 38 33589 12839 64452266
Increased viscosity of bronchial secretion 34.57 12.23 12 33615 473 64464632
Affective disorder 34.23 12.23 28 33599 6552 64458553
Intervertebral disc degeneration 34.02 12.23 38 33589 13082 64452023
Granuloma 34.00 12.23 28 33599 6613 64458492
Hepatic enzyme increased 33.33 12.23 13 33614 129930 64335175
Blood immunoglobulin E increased 32.72 12.23 22 33605 3822 64461283
Fatigue 32.50 12.23 243 33384 748487 63716618
Multiple drug therapy 32.30 12.23 18 33609 2236 64462869
Gastrooesophageal reflux disease 32.19 12.23 106 33521 83037 64382068
Congestive cardiomyopathy 32.18 12.23 33 33594 10311 64454794
Toxicity to various agents 31.79 12.23 309 33318 363204 64101901
PO2 decreased 31.78 12.23 19 33608 2694 64462411
Rash 31.29 12.23 128 33499 458421 64006684
Asthmatic crisis 30.69 12.23 16 33611 1740 64463365
Medication error 30.40 12.23 75 33552 49891 64415214
Exercise tolerance decreased 30.38 12.23 28 33599 7682 64457423
Blood pressure inadequately controlled 30.32 12.23 24 33603 5360 64459745
Blood pH decreased 30.03 12.23 22 33605 4380 64460725
Oropharyngeal candidiasis 29.95 12.23 15 33612 1500 64463605
Systemic lupus erythematosus 29.68 12.23 3 33624 77609 64387496
Depressive symptom 29.61 12.23 22 33605 4474 64460631
Acute respiratory failure 29.37 12.23 74 33553 49860 64415245
Respiratory tract inflammation 28.88 12.23 12 33615 778 64464327
Anaemia 28.87 12.23 101 33526 378579 64086526
Lipohypertrophy 28.85 12.23 12 33615 780 64464325
Synovitis 28.77 12.23 8 33619 99082 64366023
Rhinorrhoea 28.37 12.23 82 33545 59887 64405218
Breast neoplasm 27.95 12.23 12 33615 844 64464261
Hypercholesterolaemia 27.62 12.23 37 33590 15336 64449769
Drug interaction 27.00 12.23 298 33329 361785 64103320
Ligament pain 26.71 12.23 8 33619 195 64464910
Product use issue 26.52 12.23 24 33603 151691 64313414
Cyanosis 26.41 12.23 44 33583 22111 64442994
Supraventricular extrasystoles 26.30 12.23 23 33604 5892 64459213
Kyphosis 26.07 12.23 16 33611 2377 64462728
Eosinophilic bronchitis 25.66 12.23 9 33618 366 64464739
Drug level above therapeutic 25.15 12.23 24 33603 6877 64458228
Heart rate increased 25.09 12.23 110 33517 98565 64366540
Stomatitis 24.93 12.23 13 33614 109592 64355513
Respiratory tract congestion 24.71 12.23 36 33591 16129 64448976
Wolff-Parkinson-White syndrome 24.64 12.23 8 33619 256 64464849
Stress cardiomyopathy 24.32 12.23 27 33600 9230 64455875
Total lung capacity abnormal 23.96 12.23 7 33620 156 64464949
Hypoacusis 23.94 12.23 46 33581 25821 64439284
Treatment failure 23.55 12.23 16 33611 116800 64348305
Cushingoid 23.19 12.23 24 33603 7579 64457526
Death 23.17 12.23 152 33475 482553 63982552
Adrenal suppression 22.93 12.23 12 33615 1315 64463790
Oligoarthritis 22.84 12.23 8 33619 324 64464781
Arrhythmia 22.77 12.23 70 33557 52874 64412231
Sinus pain 22.47 12.23 15 33612 2574 64462531
Obesity 22.10 12.23 39 33588 20523 64444582
Tachyarrhythmia 22.04 12.23 21 33606 6005 64459100
Blood bicarbonate decreased 21.92 12.23 19 33608 4810 64460295
Thrombocytopenia 21.92 12.23 53 33574 223748 64241357
Clonic convulsion 21.89 12.23 11 33616 1108 64463997
Viral infection 21.72 12.23 54 33573 36086 64429019
Therapeutic product effect decreased 21.69 12.23 17 33610 115334 64349771
Pleural rub 21.62 12.23 5 33622 42 64465063
Generalised tonic-clonic seizure 21.32 12.23 57 33570 39800 64425305
Glossodynia 21.22 12.23 4 33623 64692 64400413
Dyspnoea at rest 21.17 12.23 21 33606 6308 64458797
Swelling 20.87 12.23 32 33595 160186 64304919
Appetite disorder 20.80 12.23 21 33606 6440 64458665
Intentional product use issue 20.68 12.23 12 33615 95352 64369753
Status epilepticus 20.64 12.23 39 33588 21624 64443481
Ventricular tachycardia 20.38 12.23 51 33576 34214 64430891
Pancytopenia 20.27 12.23 27 33600 143282 64321823
Hypoventilation 20.22 12.23 20 33607 5986 64459119
Pericarditis 20.21 12.23 4 33623 62512 64402593
Arteriosclerosis coronary artery 20.08 12.23 32 33595 15497 64449608
Influenza 20.07 12.23 109 33518 106422 64358683
Neuropathy peripheral 20.05 12.23 19 33608 117506 64347599
Sputum increased 20.03 12.23 16 33611 3619 64461486
Hypokalaemia 19.87 12.23 120 33507 121783 64343322
Acute kidney injury 19.81 12.23 145 33482 449095 64016010
Gastric atony 19.68 12.23 3 33624 0 64465105
Antasthmatic drug level above therapeutic 19.68 12.23 3 33624 0 64465105
Electrocardiogram ST segment depression 19.38 12.23 17 33610 4372 64460733
Impaired healing 19.28 12.23 4 33623 60469 64404636
Tonic convulsion 19.04 12.23 12 33615 1869 64463236
Arthropathy 19 12.23 21 33606 120946 64344159
Oesophagogastroduodenoscopy 18.98 12.23 6 33621 176 64464929
Bronchitis chronic 18.93 12.23 16 33611 3916 64461189
Pertussis 18.84 12.23 9 33618 812 64464293
Eosinophilic pneumonia 18.77 12.23 17 33610 4560 64460545
Eosinophilic pneumonia chronic 18.43 12.23 7 33620 358 64464747
Product use in unapproved indication 17.95 12.23 41 33586 176577 64288528
Presbyacusis 17.86 12.23 13 33614 2562 64462543
Paranasal sinus hypersecretion 17.86 12.23 14 33613 3082 64462023
Left ventricular failure 17.86 12.23 22 33605 8395 64456710
Oxygen saturation decreased 17.79 12.23 106 33521 107070 64358035
Completed suicide 17.66 12.23 59 33568 224355 64240750
Perfume sensitivity 17.53 12.23 8 33619 651 64464454
Drug ineffective 17.47 12.23 321 33306 839926 63625179
Ventricular extrasystoles 17.25 12.23 32 33595 17497 64447608
Ankle fracture 17.25 12.23 29 33598 14681 64450424
Adjustment disorder 17.12 12.23 13 33614 2732 64462373
Bronchitis 17.06 12.23 106 33521 108637 64356468
Lung diffusion disorder 16.93 12.23 5 33622 116 64464989
Pulmonary congestion 16.86 12.23 38 33589 23842 64441263
Ventricular arrhythmia 16.74 12.23 20 33607 7395 64457710
Allergic cough 16.71 12.23 7 33620 463 64464642
Ocular discomfort 16.69 12.23 15 33612 3984 64461121
Respiratory tract infection 16.59 12.23 50 33577 37357 64427748
Glaucoma 16.28 12.23 30 33597 16318 64448787
Macrocytosis 16.15 12.23 12 33615 2440 64462665
Lipid metabolism disorder 16.10 12.23 6 33621 291 64464814
Nasal septum deviation 15.98 12.23 10 33617 1538 64463567
Nasal polyps 15.91 12.23 14 33613 3615 64461490
Gastrointestinal disorder 15.90 12.23 14 33613 89695 64375410
Contraindicated product prescribed 15.86 12.23 9 33618 1158 64463947
Injection site pain 15.74 12.23 21 33606 111387 64353718
Haemoglobin decreased 15.54 12.23 51 33576 195012 64270093
Hyperkalaemia 15.40 12.23 18 33609 101111 64363994
Bronchitis bacterial 15.17 12.23 9 33618 1258 64463847
Nasal discharge discolouration 14.84 12.23 10 33617 1744 64463361
Wound 14.72 12.23 11 33616 76466 64388639
Deep vein thrombosis 14.68 12.23 20 33607 105162 64359943
Lung perforation 14.66 12.23 4 33623 69 64465036
Increased bronchial secretion 14.58 12.23 12 33615 2830 64462275
Flail chest 14.45 12.23 4 33623 73 64465032
Nasal oedema 14.31 12.23 8 33619 1000 64464105
Eosinophilia 14.24 12.23 48 33579 38028 64427077
Burns third degree 14.24 12.23 6 33621 403 64464702
Urogenital haemorrhage 14.24 12.23 7 33620 673 64464432
Injection site hypoaesthesia 14.18 12.23 6 33621 407 64464698
Dermatitis allergic 14.14 12.23 27 33600 15082 64450023
Transaminases increased 14.11 12.23 3 33624 44591 64420514
Diabetes mellitus inadequate control 14.03 12.23 33 33594 21288 64443817
Intentional dose omission 14.02 12.23 16 33611 5636 64459469
Diabetes mellitus 13.89 12.23 70 33557 66404 64398701
Hypoxia 13.87 12.23 86 33541 88063 64377042
Seizure 13.64 12.23 140 33487 166752 64298353
White blood cell count decreased 13.46 12.23 40 33587 157797 64307308
Inguinal hernia repair 13.35 12.23 5 33622 246 64464859
Respiratory alkalosis 13.16 12.23 13 33614 3884 64461221
Postictal state 12.98 12.23 9 33618 1644 64463461
Septic shock 12.84 12.23 22 33605 105415 64359690
Food allergy 12.76 12.23 18 33609 7833 64457272
Upper respiratory tract infection 12.73 12.23 73 33554 72712 64392393
Fungal disease carrier 12.70 12.23 5 33622 282 64464823
Crepitations 12.64 12.23 18 33609 7897 64457208
Transient ischaemic attack 12.58 12.23 51 33576 44131 64420974
Epidural lipomatosis 12.56 12.23 7 33620 870 64464235
Arthralgia 12.56 12.23 159 33468 442101 64023004
Multiple sclerosis relapse 12.55 12.23 3 33624 41132 64423973
Labelled drug-drug interaction medication error 12.25 12.23 32 33595 22030 64443075

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03DA04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DA05 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DA54 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DA55 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DA74 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DB04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines and adrenergics
ATC R03DB05 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines and adrenergics
FDA CS M0023046 Xanthines
CHEBI has role CHEBI:35523 bronchodilator
CHEBI has role CHEBI:38147 cardiotonic drugs
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D010726 Phosphodiesterase Inhibitors
MeSH PA D020011 Protective Agents
MeSH PA D058914 Purinergic Antagonists
MeSH PA D058915 Purinergic P1 Receptor Antagonists
MeSH PA D019141 Respiratory System Agents
MeSH PA D014665 Vasodilator Agents
FDA EPC N0000175790 Methylxanthine
CHEBI has role CHEBI:35620 vasodilator agents
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:49167 anti-asthmatic drugs
CHEBI has role CHEBI:50218 phosphodiesterase inhibitors
CHEBI has role CHEBI:50846 Immunologic factor
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:67079 anti-inflammatory agents
CHEBI has role CHEBI:71232 adenosine receptor antagonists
CHEBI has role CHEBI:76946 fungal metabolites
CHEBI has role CHEBI:85234 human blood serum metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bronchospasm indication 4386001
Disorder of lung indication 19829001 DOID:850
Bronchitis indication 32398004 DOID:6132
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Asthma night-time symptoms indication 395022009
Asthma management indication 406162001
Acute exacerbation of asthma indication 708038006
Asthma-chronic obstructive pulmonary disease overlap syndrome indication 10692761000119107
COPD Associated with Chronic Bronchitis indication
Chronic Obstructive Pulmonary Disease with Bronchospasms indication
Apnea in the newborn off-label use 13094009
Neonatal Mixed Apnea off-label use
Goiter contraindication 3716002 DOID:12176
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Peptic ulcer contraindication 13200003 DOID:750
Hepatic encephalopathy contraindication 13920009 DOID:13413
Hyperkalemia contraindication 14140009
Pulmonary edema contraindication 19242006 DOID:11396
Hashimoto thyroiditis contraindication 21983002
Myocardial infarction contraindication 22298006 DOID:5844
Acute tuberculosis contraindication 25629007
Shock contraindication 27942005
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypothyroidism contraindication 40930008 DOID:1459
Third trimester pregnancy contraindication 41587001
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Multiple organ failure contraindication 57653000
Hepatic failure contraindication 59927004
Poisoning by phenobarbital contraindication 64921004
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Dermatitis herpetiformis contraindication 111196000 DOID:8505
Seizure disorder contraindication 128613002
Cystic fibrosis contraindication 190905008 DOID:1485
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Sepsis syndrome contraindication 238150007
Hypocomplementemic urticarial vasculitis contraindication 239945009
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Continuous fever contraindication 271751000
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Smoking cessation assistance contraindication 384742004
Angle-closure glaucoma contraindication 392291006 DOID:13550
Breastfeeding (mother) contraindication 413712001
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Porphyria contraindication 418470004
Hypertensive urgency contraindication 443482000
Smokes tobacco daily contraindication 449868002
Severe Hypoxemia contraindication
Theophylline Toxicity contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.46 acidic
pKa2 3.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
cGMP-inhibited 3',5'-cyclic phosphodiesterase A Enzyme INHIBITOR Ki 3.85 WOMBAT-PK CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme INHIBITOR Ki 4.11 WOMBAT-PK CHEMBL
Adenosine receptor A1 GPCR ANTAGONIST Ki 9.22 CHEMBL CHEMBL
Adenosine receptor A2b GPCR ANTAGONIST Ki 5.57 CHEMBL CHEMBL
Adenosine receptor A2a GPCR ANTAGONIST Ki 9.22 CHEMBL CHEMBL
Transmembrane domain-containing protein TMIGD3 Unclassified Ki 4.06 CHEMBL
Adenosine receptor A3 GPCR ANTAGONIST Ki 7.85 CHEMBL
Alkaline phosphatase, tissue-nonspecific isozyme Enzyme Ki 4.09 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.12 CHEMBL
Adenosine receptor A2a GPCR Ki 5.17 CHEMBL
Uncharacterized protein Enzyme Ki 4.11 CHEMBL
Adenosine receptor A3 GPCR Ki 4.07 CHEMBL
Adenosine receptor A1 GPCR Ki 5.42 CHEMBL
Adenosine receptor A1 GPCR Ki 5.01 CHEMBL
Adenosine A2 receptor GPCR Ki 5.88 CHEMBL
Adenosine A2b receptor GPCR Ki 4.82 CHEMBL
Adenosine receptor GPCR Ki 4.70 CHEMBL
Heart phosphodiesterase Enzyme IC50 4.04 CHEMBL
Adenosine A2a receptor GPCR Ki 4.89 CHEMBL
Adenosine receptor A2b GPCR ANTAGONIST Ki 5.25 IUPHAR
Adenosine receptor A1 GPCR Ki 6.15 CHEMBL

External reference:

IDSource
4018056 VUID
N0000146397 NUI
D00227 KEGG_DRUG
317-34-0 SECONDARY_CAS_RN
5897-66-5 SECONDARY_CAS_RN
8000-10-0 SECONDARY_CAS_RN
4018055 VANDF
4018056 VANDF
4018129 VANDF
4018130 VANDF
4018132 VANDF
C0039771 UMLSCUI
CHEBI:28177 CHEBI
TEP PDB_CHEM_ID
CHEMBL190 ChEMBL_ID
DB00277 DRUGBANK_ID
CHEMBL1370561 ChEMBL_ID
D013806 MESH_DESCRIPTOR_UI
2153 PUBCHEM_CID
413 IUPHAR_LIGAND_ID
C137DTR5RG UNII
DB01223 DRUGBANK_ID
10438 RXNORM
2086 MMSL
3058 MMSL
4172 MMSL
4173 MMSL
4175 MMSL
5563 MMSL
5564 MMSL
674 MMSL
72114 MMSL
72147 MMSL
d00142 MMSL
d00758 MMSL
000602 NDDF
000603 NDDF
000607 NDDF
000608 NDDF
111131008 SNOMEDCT_US
372810006 SNOMEDCT_US
373508009 SNOMEDCT_US
387431001 SNOMEDCT_US
45940009 SNOMEDCT_US
55867006 SNOMEDCT_US
66493003 SNOMEDCT_US
D000628 MESH_DESCRIPTOR_UI
D031210 MESH_DESCRIPTOR_UI
CHEMBL1200578 ChEMBL_ID
376 INN_ID
5967-84-0 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
THEOPHYLLINE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0820 SOLUTION 80 mg ORAL ANDA 25 sections
Theophylline HUMAN PRESCRIPTION DRUG LABEL 1 0121-4794 SOLUTION 80 mg ORAL ANDA 25 sections
THEOPHYLLINE HUMAN PRESCRIPTION DRUG LABEL 1 0121-4820 SOLUTION 80 mg ORAL ANDA 25 sections
Theophylline in Dextrose HUMAN PRESCRIPTION DRUG LABEL 2 0264-9554 INJECTION, SOLUTION 80 mg INTRAVENOUS NDA 27 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 0378-0486 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 22 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 0378-0487 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 22 sections
Aminophylline HUMAN PRESCRIPTION DRUG LABEL 1 0404-9813 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 12 sections
Aminophylline HUMAN PRESCRIPTION DRUG LABEL 1 0404-9814 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 12 sections
Aminophylline HUMAN PRESCRIPTION DRUG LABEL 1 0404-9814 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 12 sections
Aminophylline HUMAN PRESCRIPTION DRUG LABEL 1 0409-5921 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 22 sections
Aminophylline HUMAN PRESCRIPTION DRUG LABEL 1 0409-5922 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 22 sections
Theophylline Extended Release HUMAN PRESCRIPTION DRUG LABEL 1 0615-1590 TABLET, EXTENDED RELEASE 300 mg ORAL ANDA 23 sections
Theophylline Extended Release HUMAN PRESCRIPTION DRUG LABEL 1 0615-2503 TABLET, EXTENDED RELEASE 200 mg ORAL ANDA 23 sections
Theophylline HUMAN PRESCRIPTION DRUG LABEL 1 10135-604 SOLUTION 80 mg ORAL ANDA 22 sections
Theophylline HUMAN PRESCRIPTION DRUG LABEL 1 17856-0038 SOLUTION 80 mg ORAL ANDA 13 sections
ELIXOPHYLLIN Human Prescription Drug Label 1 17856-0644 LIQUID 80 mg ORAL ANDA 21 sections
Theophylline HUMAN PRESCRIPTION DRUG LABEL 1 23155-742 TABLET, EXTENDED RELEASE 450 mg ORAL ANDA 12 sections
Theophylline HUMAN PRESCRIPTION DRUG LABEL 1 27808-033 SOLUTION 80 mg ORAL ANDA 13 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 29033-001 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 22 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 29033-002 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 22 sections
TheophyllineAnhydrous HUMAN PRESCRIPTION DRUG LABEL 1 42858-701 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 25 sections
TheophyllineAnhydrous HUMAN PRESCRIPTION DRUG LABEL 1 42858-702 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 25 sections
Theophylline Human Prescription Drug Label 1 46708-025 TABLET, EXTENDED RELEASE 300 mg ORAL ANDA 21 sections
Theophylline Human Prescription Drug Label 1 46708-026 TABLET, EXTENDED RELEASE 450 mg ORAL ANDA 21 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 51407-318 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 22 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 51407-319 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 22 sections
AMINOPHYLLINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1204 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 12 sections
AMINOPHYLLINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1341 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 12 sections
Theo-24 HUMAN PRESCRIPTION DRUG LABEL 1 52244-100 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 25 sections
Theo-24 HUMAN PRESCRIPTION DRUG LABEL 1 52244-200 CAPSULE, EXTENDED RELEASE 200 mg ORAL ANDA 25 sections